vs
因美纳（ILMN）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
因美纳的季度营收约是Revvity的1.4倍（$1.1B vs $772.1M），Revvity净利率更高（12.7% vs 12.3%，领先0.5%），Revvity同比增速更快（5.9% vs 4.8%），因美纳自由现金流更多（$251.0M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs -1.3%）
因美纳是总部位于美国加利福尼亚州圣迭戈的生物技术企业，成立于1998年4月，专注研发、生产及销售用于分析基因变异与生物功能的集成系统，产品及服务覆盖测序、基因分型、基因表达、蛋白质组学等领域，业务遍及全球超155个国家和地区。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ILMN vs RVTY — 直观对比
营收规模更大
ILMN
是对方的1.4倍
$772.1M
营收增速更快
RVTY
高出1.0%
4.8%
净利率更高
RVTY
高出0.5%
12.3%
自由现金流更多
ILMN
多$89.2M
$161.8M
两年增速更快
RVTY
近两年复合增速
-1.3%
损益表 — Q1 FY2027 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $772.1M |
| 净利润 | $134.0M | $98.4M |
| 毛利率 | 66.1% | — |
| 营业利润率 | 19.2% | 14.5% |
| 净利率 | 12.3% | 12.7% |
| 营收同比 | 4.8% | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | $0.87 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ILMNRVTY
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.2B | $772.1M | ||
| Q3 25 | — | $698.9M | ||
| Q2 25 | — | $720.3M | ||
| Q1 25 | — | $664.8M | ||
| Q4 24 | $1.1B | $729.4M | ||
| Q3 24 | $1.1B | $684.0M | ||
| Q2 24 | $1.1B | $691.7M |
净利润ILMNRVTY
| Q1 26 | $134.0M | — | ||
| Q4 25 | $334.0M | $98.4M | ||
| Q3 25 | — | $46.7M | ||
| Q2 25 | — | $53.9M | ||
| Q1 25 | — | $42.2M | ||
| Q4 24 | $186.0M | $94.6M | ||
| Q3 24 | $705.0M | $94.4M | ||
| Q2 24 | $-2.0B | $55.4M |
毛利率ILMNRVTY
| Q1 26 | 66.1% | — | ||
| Q4 25 | 65.5% | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | 65.9% | — | ||
| Q3 24 | 69.0% | 56.3% | ||
| Q2 24 | 64.8% | 55.7% |
营业利润率ILMNRVTY
| Q1 26 | 19.2% | — | ||
| Q4 25 | 17.4% | 14.5% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | 12.6% | ||
| Q1 25 | — | 10.9% | ||
| Q4 24 | 15.8% | 16.3% | ||
| Q3 24 | 68.6% | 14.3% | ||
| Q2 24 | -147.2% | 12.4% |
净利率ILMNRVTY
| Q1 26 | 12.3% | — | ||
| Q4 25 | 28.8% | 12.7% | ||
| Q3 25 | — | 6.7% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | — | 6.4% | ||
| Q4 24 | 16.8% | 13.0% | ||
| Q3 24 | 65.3% | 13.8% | ||
| Q2 24 | -178.8% | 8.0% |
每股收益（稀释后）ILMNRVTY
| Q1 26 | $0.87 | — | ||
| Q4 25 | $2.16 | $0.86 | ||
| Q3 25 | — | $0.40 | ||
| Q2 25 | — | $0.46 | ||
| Q1 25 | — | $0.35 | ||
| Q4 24 | $1.16 | $0.77 | ||
| Q3 24 | $4.42 | $0.77 | ||
| Q2 24 | $-12.48 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2B | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.7B | $7.3B |
| 总资产 | $6.6B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ILMNRVTY
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.6B | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $93.0M | $1.2B | ||
| Q3 24 | $70.0M | $1.2B | ||
| Q2 24 | $74.0M | $2.0B |
股东权益ILMNRVTY
| Q1 26 | $2.7B | — | ||
| Q4 25 | $2.7B | $7.3B | ||
| Q3 25 | — | $7.4B | ||
| Q2 25 | — | $7.6B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | $2.4B | $7.7B | ||
| Q3 24 | $2.1B | $7.9B | ||
| Q2 24 | $1.4B | $7.9B |
总资产ILMNRVTY
| Q1 26 | $6.6B | — | ||
| Q4 25 | $6.6B | $12.2B | ||
| Q3 25 | — | $12.1B | ||
| Q2 25 | — | $12.4B | ||
| Q1 25 | — | $12.4B | ||
| Q4 24 | $6.3B | $12.4B | ||
| Q3 24 | $6.0B | $12.8B | ||
| Q2 24 | $6.1B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $289.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $251.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 23.0% | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | 2.16× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $1.1B | $509.4M |
8季度趋势，按日历期对齐
经营现金流ILMNRVTY
| Q1 26 | $289.0M | — | ||
| Q4 25 | $321.0M | $182.0M | ||
| Q3 25 | — | $138.5M | ||
| Q2 25 | — | $134.3M | ||
| Q1 25 | — | $128.2M | ||
| Q4 24 | $364.0M | $174.2M | ||
| Q3 24 | $316.0M | $147.9M | ||
| Q2 24 | $80.0M | $158.6M |
自由现金流ILMNRVTY
| Q1 26 | $251.0M | — | ||
| Q4 25 | $267.0M | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | $335.0M | $149.8M | ||
| Q3 24 | $284.0M | $125.6M | ||
| Q2 24 | $49.0M | $136.6M |
自由现金流率ILMNRVTY
| Q1 26 | 23.0% | — | ||
| Q4 25 | 23.0% | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | 30.3% | 20.5% | ||
| Q3 24 | 26.3% | 18.4% | ||
| Q2 24 | 4.4% | 19.7% |
资本支出强度ILMNRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | 2.6% | 3.4% | ||
| Q3 24 | 3.0% | 3.3% | ||
| Q2 24 | 2.8% | 3.2% |
现金转化率ILMNRVTY
| Q1 26 | 2.16× | — | ||
| Q4 25 | 0.96× | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 1.96× | 1.84× | ||
| Q3 24 | 0.45× | 1.57× | ||
| Q2 24 | — | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ILMN
| Product revenue | $917.0M | 84% |
| Service and other revenue | $174.0M | 16% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
